Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage

Paul Vulilliamy\textsuperscript{a,1,2}, Scarlett Gillespie\textsuperscript{a,1}, Paul C. Armstrong\textsuperscript{b}, Harriet E. Allan\textsuperscript{b}, Timothy D. Warner\textsuperscript{b}, and Karim Brohi\textsuperscript{a,2}

\textsuperscript{a}Centre for Trauma Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, E1 2AT, United Kingdom; and \textsuperscript{b}Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, E1 2AT, United Kingdom

Trauma hemorrhage is a leading cause of death and disability worldwide. Platelets are fundamental to primary hemostasis, but become profoundly dysfunctional in critically injured patients by an unknown mechanism, contributing to an acute coagulopathy which exacerbates bleeding and increases mortality. The objective of this study was to elucidate the mechanism of platelet dysfunction in critically injured patients. We found that circulating platelets are transformed into procoagulant balloons within minutes of injury, accompanied by the release of large numbers of activated microparticles which coat leukocytes. Ballooning platelets were decorated with histone H4, a damage-associated molecular pattern released in massive quantities after severe injury, and exposure of healthy platelets to histone H4 recapitulated the changes in platelet structure and function observed in trauma patients. This is a report of platelet ballooning in human disease and of a previously unrecognized mechanism by which platelets contribute to the innate response to tissue damage.

platelets | trauma | coagulopathy | histones | hemorrhage

Platelets are the primary cellular effectors of hemostasis, but become profoundly dysfunctional in critically injured patients (1–3). A global loss of platelet aggregatory function is part of an acute coagulopathy which develops within minutes of injury, exacerbates bleeding, and has a major impact on the risk of multiple-organ failure and mortality (4, 5). The mechanisms underlying trauma-induced platelet dysfunction are unknown, but appear to result from an as yet undefined soluble factor in the plasma of trauma patients (6). Current transfusion protocols use platelet concentrates to support platelet function, but these do not restore platelet responsiveness during active hemorrhage (3, 7). Despite this, platelet transfusions appear to be critical to the survival of trauma patients, but again the mechanisms responsible are unclear (8). As nearly half of the 5 million trauma deaths every year are due to hemorrhage (9–11), understanding the function of platelets in bleeding trauma patients is vital for progress in the field.

The objective of this study was to elucidate the nature of and mechanisms underpinning the phenotypic changes in platelets in critically injured patients. We examined platelets and platelet responses in blood samples taken from trauma patients immediately on arrival at the trauma center. Here we show that reduction in the ability of platelets to aggregate occurs in parallel with an increase in their procoagulant function. Using advanced image analyses, we describe the transformation of platelets into procoagulant balloons, accompanied by release of large numbers of activated microparticles which coat leukocytes. We further show that histone H4, a damage-associated molecular pattern released into the circulation as a result of tissue damage and shock (12), interacts with circulating platelets after trauma and can entirely recapitulate these phenomena through its direct action on platelet membranes. Thus we identify a central pathway responsible for inducing a profound platelet function switch in critically injured patients dependent upon extracellular histones driving platelet ballooning and activated microparticle production.

Results

Thrombin Production Is Maintained in Patients with Platelet Dysfunction Despite Procoagulant Factor Loss. We performed impedance aggregometry, thromboelastometry, and measured circulating prothrombin fragments in a cohort of 279 injured patients immediately on arrival in the trauma center; characteristics of these patients are reported in the SI Appendix, Table S1. Using unsupervised hierarchical clustering of these variables, we identified 4 high-level clusters of patients based on variations in platelet function that had distinct clinical characteristics and outcomes (Fig. 1A and B). In clusters C3 and C4, which contained the most severely injured patients and the highest rates of trauma-induced coagulopathy (TIC), platelet aggregation in response to stimulation with multiple agonists was reduced but thrombin generation was profoundly elevated (Fig. 1C). This signature alteration in platelet activity was associated with higher blood transfusion requirements, more than twice the incidence of multiple-organ dysfunction, and up to ten times higher mortality (SI Appendix, Table S1). Together these data present a paradoxical situation, where critically bleeding patients lose platelet aggregatory function but maintain the ability to generate thrombin.

Trauma Patients Develop Procoagulant Balloon Platelets Early in Severe Hemorrhage. To explore potential mechanisms underlying these observations, we performed a series of experiments on...
a prospectively recruited cohort of severely injured patients. These patients had clinical characteristics, rates of TIC, and an incidence of platelet dysfunction comparable to those in clusters C3 and C4 (SI Appendix, Table S2). We first performed transmission electron microscopy to evaluate changes in platelet morphology. Unexpectedly, we identified large numbers of balloon structures that accumulated during resuscitation and ongoing bleeding (Fig. 2A). These structures displayed loss of membrane integrity and absent cytoplasmic contents and were not present in healthy volunteers. We confirmed with imaging flow cytometry that the balloon structures were derived from platelets as they expressed the platelet-specific integrin αIβ3 and were procoagulant by annexin V binding in keeping with previous descriptions of platelet balloons (Fig. 2B and refs. 13 and 14). The proportion of balloon platelets in the circulation increased as injury severity increased (Fig. 2C) and after administration of platelet transfusions (Fig. 2D).

Platelet balloons have never been identified in human blood samples ex vivo, but have been generated in vitro and characterized as highly procoagulant (15). The ballooned structures provide a large surface area of phosphatidylserine (PS) on the outer membrane leaflet which enables assembly of the procoagulant enzyme complexes required for thrombin generation (13). In resting platelets from trauma patients on admission, the PS-expressing subset was significantly expanded compared to healthy controls (8.9 ± 1.5% vs. 3.9 ± 1.6%, P < 0.001; Fig. 2E and SI Appendix, Fig. S1). Procoagulant platelets have also been identified as a subpopulation of activated platelets which do not bind PAC-1, a monoclonal antibody targeting the ligand-binding site on the activated conformation of integrin αIβ3 (16). The trauma patients had a substantial population of P-selectin–positive/PAC-1–negative platelets, representing a greatly expanded platelet population when compared to healthy volunteers (14.5 ± 5.5% vs. 3.1 ± 1.5%, P = 0.004; Fig. 2F and SI Appendix, Fig. S1). Together, these data indicate a procoagulant ballooning process in trauma patients which had not been identified in human disease and occurs in proportion to the severity of injury.

**Balloon Formation Is Associated with Release of Platelet-Derived Microparticles Which Coat Circulating Leukocytes.** Balloons are friable structures that eventually disintegrate, leading to a surge in microparticle release (13, 17, 18). Levels of platelet-derived microparticles (PMPs) in plasma are known to be elevated in the acute phase after major injury (19, 20). Using imaging flow cytometry, we found that trauma patients’ leukocytes were coated with PMPs in numbers proportional to the numbers of circulating balloons (Fig. 3 A and B). The proportion of these PMP-covered leukocytes increased with injury severity, whereas whole-platelet leukocyte interactions were infrequent and did not increase (Fig. 3C). Whole platelets were minimally activated whereas PMPs on leukocytes were strongly positive for P-selectin and CD63, indicating that they were derived from activated platelets (Fig. 3D). Patients who later developed multiple-organ dysfunction syndrome (MODS) were more severely injured than those who recovered without organ complications [injury severity score (ISS) 39 vs. 19, P < 0.001] and had a much higher proportion of PMP-coated leukocytes (22 ± 11% vs. 10 ± 5%, P = 0.005; Fig. 3E).

We postulated that these alterations in platelet structure and function result from exposure to damage-associated molecular patterns (DAMPs), molecules which are released into the extracellular space by activated, damaged, or necrotic cells after injury and which act as a signal that damage has occurred (21). Histones are archetypal DAMPs that are released from damaged tissues into the circulation in high concentrations after severe trauma (12), affect platelet function (22, 23), and induce cytotoxicity through direct membrane disruption (24). We therefore hypothesized that histones may be responsible for platelet ballooning and microparticle release in acute traumatic coagulopathy. We focused on histone H4 in particular, as this has been shown to have the most pronounced effects on platelets and cell membranes compared to other histones (25, 26).

**Fig. 1.** Hierarchical clustering analysis of platelet function parameters in trauma patients. (A) Heatmap and dendrogram illustrating 4 major clusters of patients (C1–C4). Each column represents a patient, and each row represents a platelet function parameter. Red cells indicate values which are increased relative to the reference population; blue cells indicate values which are reduced relative to the reference population. (B) Injury characteristics and outcomes in the 4 clusters. (C) Coagulation and platelet function profile in the 4 clusters. Box plots depict median, interquartile range and 10th-90th percentiles. Dashed lines denote normal range. *P < 0.05 **P < 0.01 ***P < 0.001 vs. cluster 1, 1-way ANOVA with Tukey’s posttest for multiple comparisons.
Histone H4 Is Cytotoxic to Platelets, Inducing Sustained Cytosolic Calcium Elevation and Reducing Agonist Responses. Histone H4 was detectable on the surface of circulating platelets from trauma patients, and the degree of histone binding was strongly correlated with the size of the procoagulant subset (Fig. 4A). In vitro, exposure of platelets sourced from healthy volunteers to histone H4 at concentrations previously reported in injured humans produced sustained rises in cytosolic calcium concentrations of platelets which persisted for at least 60 min from exposure (Fig. 4B). This population could not respond to subsequent agonist stimulation (Fig. 4C). Histone-platelet interaction resulted in membrane damage, evidenced by a concentration-dependent increase in lactate dehydrogenase (LDH) release from platelets (Fig. 4D). This was not attenuated by blockade of Toll-like receptor 2 (TLR2) or TLR4, the major receptors for histones (Fig. 4E, F). Histones are known to exert on cell membranes (24, 27) like receptor 2 (TLR2) or TLR4, the major receptors for histones (23) (Fig. 4F). Histone H4-treated platelets also produced large quantities of microparticles which retained histone H4 on their surfaces (Fig. 5E-G) and expressed phosphatidylserine on their outer leaflets (Fig. 5H), suggesting that they originated from the procoagulant subset and indicating their potential to support coagulation and modulate immune cell function. These microparticles coated the surfaces of leukocytes (Fig. 5I), reflecting our observations in trauma patients. Finally, histone H4 caused a concentration-dependent release of the proinflammatory alpha granule protein platelet factor 4 (PF4) from platelets in vitro, mirroring observations of elevations in PF4 seen in plasma samples of trauma patients (SI Appendix, Fig. S3).

Discussion
The results presented in this study demonstrate a fundamental switch in platelet behavior toward a procoagulant and proinflammatory phenotype at the expense of platelet aggregation, which occurs during traumatic hemorrhage as a direct response to tissue damage. We propose a model in which histone H4 released into the circulation by mechanically damaged or ischemic tissues exerts a direct cytotoxic effect on platelets. This interaction drives platelet ballooning, leading to the release of microparticles which interact with circulating leukocytes.

Platelet balloons are thought to form at wound sites as a response to vascular injury (13, 28–30). The agonist requirements for platelet ballooning in vitro are high concentrations of collagen (or collagen-related peptide) and thrombin—conditions found at the site of endothelial damage (31). The ballooned platelet membrane maximizes the surface area for assembly of procoagulant enzyme complexes on the platelet surface, which is critical for amplification of thrombin generation at sites of injury (32). Histones have been shown to promote platelet-dependent thrombin generation (23), but have not been shown to induce ballooning. In this study, we observed interactions between histone H4 and platelets in vivo after major injury in humans, and found that this interaction induces sustained rises in cytosolic calcium levels leading to membrane ballooning and procoagulant transformation. Histone H4 is released from tissues which have been mechanically disrupted or subjected to ischemia, resulting in massive elevations in circulating histone levels after severe injury and hemorrhage (12, 33). Of the 5 proteins which make up the histone family, H4 has the most potent effects on platelets (22) and has pore-forming activity on contact with cell membranes which induces lytic cell death (26). Our data suggest that this direct membrane-toxic effect of H4 drives platelet ballooning, although other histones may also play a contributory role. This alternative mechanism accounts for the presence of balloons free in the peripheral circulation in trauma patients at sites remote from vascular damage, and provides a potential explanation for the widespread development of procoagulant platelets in other diseases which involve histone release but not collagen exposure, such as ischemia-reperfusion injury and sepsis-induced disseminated intravascular coagulation (30, 34, 35).

Due to their lack of cytoskeletal architecture, balloons are delicate structures which readily disintegrate, producing large quantities of microparticles (13, 17). Histone H4 exposure recapitulates this phenomenon. In trauma patients, we found large numbers of circulating leukocytes bound by material from activated platelets.
which was almost entirely in the form of microparticles rather than whole platelets; these interactions were most frequent in patients with severe injuries who developed MODS. Our observations build on previous reports of increased levels of circulating platelet-derived microparticles in plasma from trauma patients (19, 20, 36) and support previous findings suggesting that platelet responses can bridge coagulation and inflammatory systems to shape the immune response during acute sterile inflammation (37). Platelet-derived microparticles have been shown to have immunomodulatory effects on leukocytes (18, 38, 39), and platelet-leukocyte interactions are implicated in organ dysfunction during sterile inflammation in experimental models (40, 41). We postulate that microparticles released from histone-stimulated platelets are an additional facet of the platelet functional repertoire, allowing them to act as messengers which alert the immune response to tissue injury by interactions with circulating neutrophils and monocytes. The molecular interactions involved in these interactions and their ability to cause immunomodulation in trauma patients warrants future research.

Our findings have important implications for the management of trauma hemorrhage and our understanding of TIC. Several
authors have described a state of elevated thrombin–generating potential despite loss of procoagulant clotting factors in severely injured patients (42, 43). This study identifies ballooning platelets as the previously undefined procoagulant factor underlying this apparently paradoxical situation. Our findings illustrate that posttraumatic changes in platelet behavior are more complex than solely the impairment of platelet aggregation that has been described (1, 2). It is unclear how platelet ballooning and PMP release impact global assays of hemostasis, such as thromboelastometry, that are increasingly used to guide resuscitation (44). Although alloimmune platelets are routinely administered to bleeding patients as part of major hemorrhage protocols to support platelet function during TIC, there is uncertainty around their efficacy and mechanism of action (45, 46). Transfused platelets are exposed to the same intravascular conditions as endogenous platelets and are therefore susceptible to histone-induced procoagulant transformation. This provides one potential explanation as to why platelet transfusions do not support aggregation (3, 7) but lead to increases in circulating alpha granule proteins (3) and increases in circulating platelet balloons.

In conclusion, this study describes a dramatic phenotypic change in circulating platelets induced by histone release after major trauma. Our findings provide insights into aspects of platelet behavior previously unrecognized in trauma patients, and broaden the concept of platelet “dysfunction” during coagulopathic hemorrhage. We describe a previously undefined and fundamental component of the innate response to damage, which is manifest by the development of platelet ballooning and microparticle production. These observations have implications for the pathophysiology of trauma-induced coagulopathy and multiple-organ dysfunction, and for the future development of effective platelet therapeutics for critically bleeding patients.

Materials and Methods

Additional methodological details can be found in the SI Appendix.

Study Design. Adult trauma patients recruited into the Activation of Coagulation and Inflammation after Trauma (ACIT) study who met criteria for advanced trauma team activation at a single urban major trauma center were included in this study. Inclusion and exclusion criteria have been published previously (3, 5). The study was approved by the London – City and East Research Ethics Committee (reference 07/Q0603/29). In patients who lacked capacity, consent for participation was provided by an independent clinician prior to any study-related activities. Informed consent was then obtained from the patient or next of kin at the earliest opportunity. Blood samples were obtained in the emergency department within 2 hours of injury and processed immediately after collection. Characteristics of the study cohorts are described in the SI Appendix, Tables S1 and S2. Healthy volunteers taking no regular medication acted as a control group (reference 07/Q0702/24).

Transmission Electron Microscopy. Platelet-rich plasma was fixed in graded buffers, washed, and stored overnight in sodium cacodylate buffer. Samples were dehydrated in a graded ethanol series and then infiltrated with London Resin white resin prior to examination with a JOEL JEM-1230 microscope (JOEL USA). Further details can be found in the SI Appendix.

Flow Cytometry and Imaging Flow Cytometry. P-selectin (CD62P) expression, integrin αIIbβ3 activation, annexin V binding, and histone H4 were quantified on platelets by flow cytometry using an LSRII flow cytometer (Becton Dickinson). Platelet balloons, platelet-leukocyte interactions, and PMPs were characterized and quantified using the ImageStream® MK II imaging flow cytometer (Amnis). Antibody panels and gating strategies are described in the SI Appendix, Figs. S1 and S4.

Platelet Stimulation. Washed platelets (3 × 10⁸/mL) were recalcified to 2 mM and incubated at 37 °C under stirring conditions with vehicle or Histone H4 Human, Recombinant (New England Biolabs), at the stated concentrations. Reactions were stopped by addition of 1.2 acid-citrate-dextrose (5 mM dextrose, 6.8 mM trisodium citrate, 3.8 mM citric acid). Platelets were then prepared for flow cytometry or imaging flow cytometry as described in the SI Appendix.

Calcium Mobilization. Washed platelets were loaded with Fluo 3-AM (Biotium) for 30 min and then incubated with anti-CD42b-APC for 15 min. Platelets were then diluted 1:10 with Tyrode’s buffer with 2 mM calcium. Basal fluorescence was recorded in unstimulated platelets, and changes were quantified in real time following challenge with thrombin receptor–activating peptide 6 (TRAP) or H4 using the LSRII flow cytometer.

Data Analysis. Hierarchical clustering analysis was performed with Morpheus software (Broad Institute). Statistical analyses were performed using Prism v6.0 (GraphPad). A 2-tailed P value of <0.05 was considered significant throughout.

ACKNOWLEDGMENTS. We thank Professor Harry Heijnen for his advice and assistance in the interpretation of electron microscopy images, and Dr. Giulia Mastroianni for technical assistance with electron microscopy. This study was...
1. M. E. Kutcher et al., Characterization of platelet dysfunction after trauma. J. Trauma Acute Care Surg. 73, 13–19 (2012).
2. C. Solomon et al., Platelet function following trauma. A multiple electrode aggregometry study. Thromb. Haemost. 106, 322–330 (2011).
3. P. Vulliamy et al., Platelet transfusions reduce fibrinolysis but do not restore platelet function during trauma hemorrhage. J. Trauma Acute Care Surg. 83, 388–397 (2017).
4. K. Brohi, J. Singh, M. Heron, T. Coats, Acute traumatic coagulopathy. J. Trauma 54, 1127–1130 (2003).
5. R. Davenport et al., Functional definition and characterization of acute traumatic coagulopathy. Crit. Care Med. 39, 2652–2658 (2011).
6. C. C. Vulliamy et al., platelet transfusion reduces fibrinolysis but does not fully restore platelet function during trauma. J. Trauma Acute Care Surg. 83, 388–397 (2017).
7. H. H. Hendriksen et al., Impact of blood products on platelet function in patients with traumatic injuries: A translational study. J. Surg. Res. 214, 154–161 (2017).
8. J. C. Cardenas et al.; PROPR Study Group, Platelet transfusions improve hemostasis and survival in a study of the prospective, randomized PROPR trial. Blood Adv. 2, 1696–1704 (2018).
9. J. A. Haagsga et al., The global burden of injury: Incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Inj. Prev. 22, 1–8 (2016).
10. J. W. Cannon, Hemorrhagic shock. N. Engl. J. Med. 378, 370–379 (2018).
11. C. C. Cothren, E. E. Moore, H. B. Hedegaard, K. Meng, Epidemiology of urban trauma deaths: A comprehensive reassessment 10 years later. World J. Surg. 31, 1507–1511 (2007).
12. S. T. Abrams et al., Circulating histones are mediators of trauma-associated lung injury. Am. J. Respir. Crit. Care Med. 187, 160–169 (2013).
13. E. O. Agbani et al., Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation 132, 1414–1424 (2015).
14. N. A. Podopletova et al., Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting. Blood 128, 1745–1755 (2016).
15. M. W. Hess, P. SiJander, Procoagulant platelet balloons: Evidence from cryopreparation and electron microscopy. Histochem. Cell Biol. 115, 439–443 (2001).
16. G. L. Dale et al., Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 415, 175–179 (2002).
17. E. O. Agbani, C. M. Williams, I. Hers, A. W. Poole, Membrane ballooning in aggregated platelets is synchronised and mediates a surge in microvesiculation. Sci. Rep. 7, 2770 (2017).
18. C. Tersteeg et al., Flow-induced P60trusions (FlP60s): A platelet-derived platform for the retrieval of microcrystals by monocytes and neutrophils. Circ. Res. 114, 780–791 (2014).
19. M. Cooper et al., Microcrystals profiling in trauma patients: High level of microcrystals induce activation of platelets in vitro. Eur. J. Trauma Emerg. Surg. 10.1007/s00068-019-01111-7 (2019).
20. N. Curry, A. Raja, J. Beavis, S. Stanworth, P. Harrison, Levels of procoagulant microvesicles are elevated after traumatic injury and platelet microvesicles are negatively correlated with mortality. J. Extracell. Vesicles 3, 25625 (2014).
21. J. Manson, C. Thiemermann, K. Brohi, Trauma alarmists as activators of damage-induced inflammation. Br. J. Surg. 99 (suppl. 1), 12–20 (2012).
22. A. Caretta et al., Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb. Haemost. 110, 1035–1045 (2013).
23. F. Semeraro et al., Extracellular histones promote thrombin generation through platelet-dependent mechanisms: Involvement of platelet TRLR2 and TLR4. Blood 118, 1952–1961 (2011).
24. T. J. Kleine, A. Gladfelter, P. N. Lewis, S. A. Lewis, Histone-induced damage of a mammalian epithelium: The conductive effect. Am. J. Physiol. 268, C1114–C1125 (1995).
25. T. A. Fuchs, A. A. Bhandari, D. W. Wagner, Histones induce rapid and profound thrombocytopenia in mice. Blood 118, 3708–3714 (2011).
26. C. Silvestre-Roig et al., Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature 569, 236–240 (2019).
27. T. J. Kleine, P. N. Lewis, S. A. Lewis, Histone-induced damage of a mammalian epithelium: The role of protein and membrane structure. Am. J. Physiol. 273, C1925–C1936 (1997).
28. J. W. Heemskerk, W. M. Vuist, M. A. Feige, C. P. Reutelingsperger, T. Lindhout, Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: Evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood 90, 2615–2625 (1997).
29. J. Wester, J. J. Sixma, J. J. Geurts, H. F. Heijnen, Morphology of the hemostatic plug in human skin wounds: Transformation of the plug. Lab. Invest. 41, 182–192 (1979).
30. Y. Yuan et al., Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemia. Sci. Transl. Med. 9, eaap5681 (2017).
31. E. O. Agbani, A. W. Poole, Procoagulant platelets: Generation, function, and therapeutic targeting in thrombosis. Blood 130, 2171–2179 (2017).
32. M. Hoffman, D. M. Monroe, 3rd, A cell-based model of hemostasis. Thromb. Haemost. 85, 938–965 (2001).
33. R. Chen, R. Kang, X. G. Fan, D. Tang, Release and activity of histone in diseases. Cell Death Dis. 5, e1370 (2014).
34. H. Huang et al., Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology 54, 999–1008 (2011).
35. R. Alham et al., Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J. Am. Soc. Nephrol. 23, 1375–1388 (2012).
36. K. Balvers et al., Endogenous microparticles drive the proinflammatory host immune response in severely injured trauma patients. Shock 43, 317–321 (2015).
37. J. L. Li, A. Zarbock, A. Hidalgo, Platelets as autonomous drones for hemostatic and immune surveillance. J. Exp. Med. 214, 2193–2204 (2017).
38. E. Boilard et al., Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327, 580–583 (2010).
39. N. Mauger et al., Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis. Sci. Transl. Med. 10, eaao3089 (2018).
40. A. Zarbock, K. Singbartl, K. Ley, Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J. Clin. Invest. 116, 3211–3219 (2006).
41. M. R. Looney et al., Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J. Clin. Invest. 119, 3450–3461 (2009).
42. N. M. Dunbar, W. L. Chandler, Thrombin generation in trauma patients. Transfusion 49, 2652–2660 (2009).
43. A. A. Menezes, R. F. Vilaridi, A. P. Arkin, M. J. Cohen, Targeted clinical control of trauma patient coagulation through a thrombin dynamics model. Sci. Transl. Med. 9, eaaf5045 (2017).
44. K. Baksaa-Aaen et al.; TACTIC/INTRN Collaborators, Data-driven development of ROTEM and TEG algorithms for the management of trauma hemorrhage: A prospective observational multicenter study. Ann. Surg. 10.1097/SLA.0000000000002825 (2018).
45. M. I. Baharouglu et al.; PATCH Investigators, Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with anti-platelet therapy (PATCH): A randomised, open-label, phase 3 trial. Lancet 387, 2605–2613 (2016).
46. J. B. Holcomb et al.; PROPR Study Group, Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs. a 1:1:2 ratio and mortality in patients with severe trauma: The PROPR randomized clinical trial. JAMA 323, 471–482 (2015).